Their findings revealed that bardoxolone methyl effectively reduces IL-6 secretion in paclitaxel-resistant ovarian cancer cells and specifically inhibits the nuclear translocation of Stat3 induced by IL-6 or oncostatin M. Bardoxolone methyl treatment led to a significant reduction in the phosphorylation of Stat3, Jak2, and Src in ovarian and breast cancer cell lines exhibiting constitutive Stat3 activation. The gene discussed is SRC; the disease is ovarian cancer.